Detalles de la búsqueda
1.
Power and sample size calculation for incremental net benefit in cost effectiveness analyses with applications to trials conducted by the Canadian Cancer Trials Group.
BMC Med Res Methodol;
23(1): 179, 2023 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37537545
2.
Parametric Survival Extrapolation of Early Survival Data in Economic Analyses: A Comparison of Projected Versus Observed Updated Survival.
Value Health;
25(4): 622-629, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35365306
3.
Validating Restricted Mean Survival Time Estimates From Reconstructed Kaplan-Meier Data Against Original Trial Individual Patient Data From Trials Conducted by the Canadian Cancer Trials Group.
Value Health;
25(7): 1157-1164, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35779942
4.
Reassessing the Net Benefit of Cancer Drugs With Evolution of Evidence Using the ASCO Value Framework.
J Natl Compr Canc Netw;
19(7): 815-820, 2021 02 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-33636693
5.
Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time.
J Natl Compr Canc Netw;
18(3): 278-285, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32135516
6.
Experiences of gender-diverse youth during the COVID-19 pandemic in Canada: A longitudinal qualitative study.
PLoS One;
18(11): e0294337, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37971999
7.
Examining the association between oncology drug clinical benefit and the time to public reimbursement.
Cancer Med;
11(2): 380-391, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34850587
8.
Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis.
Crit Rev Oncol Hematol;
173: 103660, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35341985
9.
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.
JAMA Netw Open;
4(2): e2033004, 2021 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33570573
10.
Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to Assess the Value of Abiraterone and Enzalutamide in Advanced Prostate Cancer.
JCO Oncol Pract;
16(2): e201-e210, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32045549
11.
Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
JAMA Netw Open;
2(7): e196803, 2019 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31290990
12.
Assessment of Whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit: An Analysis of Randomized Clinical Trials.
JAMA Oncol;
5(8): 1188-1194, 2019 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31095255
13.
Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations.
Cancer Med;
8(4): 1584-1593, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30848108
Resultados
1 -
13
de 13
1
Próxima >
>>